In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Maria C AlmeidaNeuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA.ORCID 0000-0002-2012-3169 Tian WangF.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4007-7710 Andrew P LonghiniNeuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA.ORCID 0000-0002-0599-5030 Samuel LoboCenter for Mathematics, Computing and Cognition (CMCC), Federal University of ABC, São Bernardo do Campo, SP, Brazil.ORCID 0000-0002-1162-8798 Carolina M CamargoNeuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA.ORCID 0000-0002-5918-4081 Eric D TinkleNeuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA.ORCID 0009-0005-1641-9572 Mookwang KwonNeuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA.ORCID 0009-0004-0937-4022 Guilherme Z DuarteCenter for Natural and Human Sciences (CCNH), Federal University of ABC, São Bernardo do Campo, SP, Brazil.ORCID 0009-0004-4014-0419 Isabel O HirschCenter for Natural and Human Sciences (CCNH), Federal University of ABC, São Bernardo do Campo, SP, Brazil.ORCID 0009-0009-0078-657X Cesar A J RibeiroCenter for Natural and Human Sciences (CCNH), Federal University of ABC, São Bernardo do Campo, SP, Brazil.ORCID 0000-0003-4604-9945 Fernando A OliveiraCenter for Mathematics, Computing and Cognition (CMCC), Federal University of ABC, São Bernardo do Campo, SP, Brazil.ORCID 0000-0002-1632-4267 M Scott ShellDepartment of Chemical Engineering, University of California Santa Barbara, Santa Barbara, CA, USA.ORCID 0000-0002-0439-1534 Joan-Emma SheaDepartment of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, CA, USA.ORCID 0000-0002-9801-9273 Judith A SteenF.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8167-0772 Kenneth S KosikNeuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA.ORCID 0000-0003-3224-5179 Daniel C CarrettieroNeuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA.ORCID 0000-0002-6546-2949 Funding
Molecular Basis of the Tau Aggregation PathwayR01AG056058 · NIA · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI Songi Han, KENNETH Stephen KOSIK · 2017 to 2026
$6.4MIntegrated Platform to study Neurodegeneration in Alzheimer’s DiseaseR01AG071858 · NIA · BOSTON CHILDREN'S HOSPITAL · PI STEEN, JUDITH A · 2021 to 2025
$3.9MNIA NIH HHS R01 AG056058NIA NIH HHS R01 AG071858
6 · The paper itselfAbstract
Protein aggregation, impaired degradation, and immune activation are central hallmarks of neurodegenerative diseases, yet how these processes are coordinated remains unclear. Here, we identify Immune-Protein Degradation Bodies (I-PDBs), a previously unrecognized class of BAG2-driven, phase-separated organelles that integrate protein quality control with adaptive immunity. IFNγ induce I-PDB formation at the endoplasmic reticulum (ER), where they concentrate immunoproteasome components, MHC-I peptide-loading machinery, and ER-associated chaperones. I-PDBs redirect proteostatic cargo from centrosomal aggregation pathways to spatially restricted degradation sites optimized for antigenic peptide generation, coupling selective substrate clearance to CD8
Indexed as
antigen presentationimmunoproteasomeinflammationInterferon gammaliquid-liquid phase separationmembraneless organelleneurodegenerationtauopathy
Identifiers
PMID42094418
PMCPMC13142436
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390